Related Experiment Video

Updated: Aug 30, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K

Antibody-drug conjugates: beyond current approvals and potential future strategies

Siddharth Menon1,2, Sagun Parakh1,2, Andrew M Scott1,2

  • 1Olivia Newton-John Cancer Centre at Austin Health, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg Victoria 3084, Australia.

Exploration of Targeted Anti-Tumor Therapy
|September 1, 2022
PubMed

Insights

Antibody-drug conjugates (ADCs) show promise in treating various cancers by targeting cancer cells. This review covers ADCs in gastrointestinal, genitourinary cancers, and glioblastoma, exploring future developments including novel targets and combinations.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Recent approvals highlight the growing importance of antibody-drug conjugates (ADCs) in cancer therapy.
  • ADCs leverage targeted delivery of cytotoxic payloads to oncogenic antigens, enhancing therapeutic windows.

Purpose of the Study:

  • To review the clinical activity of ADCs in specific cancer types: gastrointestinal (GI), genitourinary (GU), and glioblastoma (GBM).
  • To provide insights into future ADC development, including novel antigen targets and combination strategies.

Main Methods:

  • Literature review of clinical activity and preclinical/early phase testing of ADCs.
  • Focus on emerging ADC strategies and combinations with immuno-oncology (IO) agents.

Main Results:

  • ADCs demonstrate clinical activity in GI, GU cancers, and GBM.
  • Substantial preclinical and early-phase research is underway for novel ADCs and combination therapies.

Conclusions:

  • ADCs represent a significant advancement in oncology, with ongoing development expanding their application.
  • Future directions include targeting novel antigens within the tumor microenvironment (TME) and combining ADCs with IO agents for improved efficacy.
Keywords:
Antibody-drug conjugatesimmunotherapytumour microenvironment

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.8K
Laboratory Scale Production and Purification of a Therapeutic Antibody09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.5K

Related Concept Videos

Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
291
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.3K
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.2K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.0K
Principles of Drug Action01:24

Principles of Drug Action

Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.4K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
996